KNE and KNBIF Related Headlines
Go Back- Kane Biotech Announces Second Quarter 2026 Financial Results
- Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
- Kane Biotech Announces Engagement of DNA Advisors
- Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
- Kane Biotech Announces First Quarter 2026 Financial Results
- Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
- Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
- Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
- Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
- Kane Biotech partners with Marathon Medical for US government markets
- Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
- Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
- Kane Biotech Expands Commercial Activities in the United States
- Kane Biotech receives FDA clearance for wound cleanser product
- Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
- Kane Biotech Restarts Commercial Activities and Strengthens North American Management
- Kane Biotech closes $700,000 private placement with company insider
- Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
- Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
- Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
- Kane Biotech Announces Third Quarter 2025 Financial Results
- Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
KNE and KNBIF Related Press Releases
Go Back- Kane Biotech Announces Second Quarter 2026 Financial Results
- Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
- Kane Biotech Announces Engagement of DNA Advisors
- Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
- Kane Biotech Announces First Quarter 2026 Financial Results
- Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
- Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
- Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
- Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
- Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
- Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
- Kane Biotech Expands Commercial Activities in the United States
- Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
- Kane Biotech Restarts Commercial Activities and Strengthens North American Management
- Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
- Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
- Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
- Kane Biotech Announces Third Quarter 2025 Financial Results
- Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
